Theranostic nanoparticles based on bioreducible polyethylenimine-coated iron oxide for reduction-responsive gene delivery and magnetic resonance imaging

Li, Dan; Tang, Xin; Pulli, Benjamin; Lin, Chao; Zhao, Peng; Cheng, Jun; Lv, Zhongwei; Yuan, Xueyu; Luo, Qiong; Cai, Haidong; Ye, Meng

doi:10.2147/ijn.s61463

Cited by 22 publications

(7 citation statements)

References 43 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, iron oxide NPs were coated in a disulfide-containing polyethylimine (PEI) exterior to create redox-sensitive gene delivery vehicles 77 . PEI is a cationic polymer that can bind nucleic acids through electrostatic interactions.…”

Section: Therapeutic Spions For Cancer Treatmentmentioning

confidence: 99%

Magnetite nanoparticles for cancer diagnosis, treatment, and treatment monitoring: recent advances

2016

View full text Add to dashboard Cite

The development of nanoparticles (NPs) for use in all facets of oncological disease detection and therapy has shown great progress over the past two decades. NPs have been tailored for use as contrast enhancement agents for imaging, drug delivery vehicles, and most recently as a therapeutic component in initiating tumor cell death in magnetic and photonic ablation therapies. Of the many possible core constituents of NPs, such as gold, silver, carbon nanotubes, fullerenes, manganese oxide, lipids, micelles, etc., iron oxide (or magnetite) based NPs have been extensively investigated due to their excellent superparamagnetic, biocompatible, and biodegradable properties. This review addresses recent applications of magnetite NPs in diagnosis, treatment, and treatment monitoring of cancer. Finally, some views will be discussed concerning the toxicity and clinical translation of iron oxide NPs and the future outlook of NP development to facilitate multiple therapies in a single formulation for cancer theranostics.

show abstract

Section: Therapeutic Spions For Cancer Treatmentmentioning

confidence: 99%

Magnetite nanoparticles for cancer diagnosis, treatment, and treatment monitoring: recent advances

2016

View full text Add to dashboard Cite

show abstract

“…For increasing the degradability, a disulfide bond that is stable in the oxidative extracellular environment, but reduced and degraded in the intracellular environment, was introduced in the PEI. 24) In our study, dopamine-conjugated HA was stably coated on the stent surface, followed by the immobilization of MSNs on the HA surface of the stent. This was accomplished due to the fact that HA-linked dopamine forms a strong bond with various inorganic/organic surfaces.…”

Section: Discussionmentioning

confidence: 95%

Novel Fabrication of MicroRNA Nanoparticle-Coated Coronary Stent for Prevention of Post-Angioplasty Restenosis

et al. 2016

View full text Add to dashboard Cite

Background and ObjectivesMicroRNA 145 is known to be responsible for cellular proliferation, and its enhanced expression reportedly inhibits the retardation of vascular smooth muscle cell growth specifically. In this study, we developed a microRNA 145 nanoparticle immobilized, hyaluronic acid (HA)-coated stent.Materials and MethodsFor the gene therapy, we used disulfide cross-linked low molecular polyethylenimine as the carrier. The microRNA 145 was labeled with YOYO-1 and the fluorescent microscopy images were obtained. The release of microRNA 145 from the stent was measured with an ultra violet spectrophotometer. The downstream targeting of the c-Myc protein and green fluorescent protein was determined by Western blotting. Finally, we deployed microRNA 145/ssPEI nanoparticles immobilized on HA-coated stents in the balloon-injured external iliac artery in a rabbit restenosis model.ResultsCellular viability of the nanoparticle-immobilized surface tested using A10 vascular smooth muscle cells showed that MSN exhibited negligible cytotoxicity. In addition, microRNA 145 and downstream signaling proteins were identified by western blots with smooth muscle cell (SMC) lysates from the transfected A10 cell, as the molecular mechanism for decreased SMC proliferation that results in the inhibition of in-stent restenosis. MicroRNA 145 released from the stent suppressed the growth of the smooth muscle at the peri-stent implantation area, resulting in the prevention of restenosis at the post-implantation. We investigated the qualitative analyses of in-stent restenosis in the rabbit model using micro-computed tomography imaging and histological staining.ConclusionMicroRNA 145-eluting stent mitigated in-stent restenosis efficiently with no side effects and can be considered a successful substitute to the current drug-eluting stent.

show abstract

“…Furthermore, it is important to highlight that MFCEA can be studied as nanocarrier for drug delivery, as well as for magnetic hyperthermia and nuclear MRI because of its magnetic property [15,[64][65][66][67][68]. Interestingly, MFCEA can be included in a multifunctional approach, combining therapy and diagnosis simultaneously [69][70][71][72][73]. Besides its versatility and applicability for TNBC, MFCEA might benefit patients with different neoplasias.…”

Section: Discussionmentioning

confidence: 99%

Anti-CEA tagged iron nanoparticles for targeting triple-negative breast cancer

et al. 2021

View full text Add to dashboard Cite

Systemic therapy is generally required for breast cancer. However, treatment toxicity and side effects are a concern, especially for triple-negative breast cancer (TNBC), a subtype that usually develops resistance to chemotherapy. To overcome this issue, new nanoformulations capable of targeting cancer cells have been developed and alternative biomarkers have been explored as target molecules for TNBC management. In this study, we performed an in vivo assay in a murine orthotopic TNBC model to evaluate the targeting ability of anti-carcinoembryonic antigen (anti-CEA) loaded nanoparticles (labelled MFCEA), which had been previously synthetized by our research group. 4T1 cells were injected in the mammary gland of balb-c mice, and tumors were evaluated for CEA expression by immunohistochemistry. Tumor-bearing mice received targeted (MFCEA) and non-targeted (MF) nanoparticles intraperitoneally. Tumors were removed 1, 4, 15 and 24 h after treatment, and Prussian blue iron staining was performed. Our results showed, as far as we know for the first time, that 4T1 induced tumors are CEA positive, and this opens up new prospects for treating TNBC. Furthermore, MFCEA nanoparticles were able to target malignant tissue and were retained in the tumor for longer than MF nanoparticles. The retention property of MFCEA, together with the absence of toxicity observed in the MTT assay, make these nanoparticles a promising device for management of CEA positive tumors and perhaps for TNBC. Nevertheless, further studies must be carried out to improve their performance and ensure safety for clinical studies.

show abstract

Theranostic nanoparticles based on bioreducible polyethylenimine-coated iron oxide for reduction-responsive gene delivery and magnetic resonance imaging

Cited by 22 publications

References 43 publications

Magnetite nanoparticles for cancer diagnosis, treatment, and treatment monitoring: recent advances

Magnetite nanoparticles for cancer diagnosis, treatment, and treatment monitoring: recent advances

Novel Fabrication of MicroRNA Nanoparticle-Coated Coronary Stent for Prevention of Post-Angioplasty Restenosis

Anti-CEA tagged iron nanoparticles for targeting triple-negative breast cancer

Contact Info

Product

Resources

About